Here is the design of a clinical trial:

Official Title: Optimizing the Antibiotic Treatment of Uncomplicated Acute Appendicitis: a Prospective Randomised Multicenter Study (The APPAC II Study)

Included conditions:
- Acute Appendicitis

Study Armgroups:
- {'label': 'Intravenous & per oral antibiotics', 'type': 'ACTIVE_COMPARATOR', 'description': 'Ertapenem 1 g x 1 for two days i.v. followed by p.o. levofloxacin 500 mg x 1 and metronidazole 500 mg x 3 for 5 days, duration of treatment one week.', 'interventionNames': ['Drug: Ertapenem']}
- {'label': 'Per oral antibiotics', 'type': 'ACTIVE_COMPARATOR', 'description': 'Moxifloxacin 400 mg x 1 foe seven days, duration of treatment one week.', 'interventionNames': ['Drug: Moxifloxacin']}

Interventions:
- {'type': 'DRUG', 'name': 'Ertapenem', 'description': 'I.v. ertapenem 1 g for 2 days followed by p.o. levofloxacin 500 mg x1 and metronidazole 500 mg x 3 for 5 days', 'armGroupLabels': ['Intravenous & per oral antibiotics'], 'otherNames': ['Levofloxacin', 'Metronidazole']}
- {'type': 'DRUG', 'name': 'Moxifloxacin', 'description': 'P.o. moxifloxacin 400 mg x1 for 7 days', 'armGroupLabels': ['Per oral antibiotics']}

Primary Outcomes:
- {'measure': 'Treatment success', 'description': 'The resolution of acute uncomplicated appendicitis with allocated antibiotic treatment. Treatment success is defined as discharge from the hospital without the need for surgical intervention after the primary hospitalisation and no recurrent appendicitis during one-year follow-up.', 'timeFrame': '1 year'}

Please estimate the sample size based on the assumption: 
The power is set at 0.9 (1-β) with a one-sided significance level (α) of 0.05 and an estimated dropout rate of 15%.
Sample size calculation
        As the primary objective of the study is to demonstrate that p.o. antibiotics are non-inferior compared to a combination of i.v. and p.o. antibiotic therapy, a non-inferiority design is used and sample size calculations were based on non-inferiority test for binomial proportion. Sample size was calculated from an estimated success rate of 73% for i.v. + p.o. antibiotic group during the one year follow-up based on the results of our previous APPAC trial [10]. The hypothetical difference between the two groups ((i.v. + p.o.) â (p.o.)) was set to zero and non-inferiority margin was set to 6 percentage points. We estimated that a total of 469 patients would yield a power of 0.9 (1-Î²) to establish whether p.o. antibiotic therapy was non-inferior to i.v. + p.o. using a one-sided significance level (Î±) of 0.05. With an estimated dropout rate of 15% total of 552 patients, 276 patients per group will be enrolled in the study. Targeted minimum sample size per study hospital will be 20 patients.